Forest Hills Lab is an innovative regenerative therapy company composed of two distinct divisions specializing in Neuroscience and Aesthetics. We develop safe and effective neurodegenerative treatments alongside innovative aesthetic products that improve the quality of life in our rapidly-aging world.
Our global network spans offices in Hong Kong, where we are headquartered, Singapore, Korea, and the United States.
FHLTherapeutics is focused on developing and commercializing safe, disease-modifying therapies for devastating neurodegenerative diseases like Alzheimer's. One pipeline candidate is approved by US FDA to begin Phase 2 trials while another is currently undertaking Phase 1 safety trials. Drug candidate development is advanced on an open development platform that emphasizes external partnerships and co-development.
FHL Aesthetics develops and markets a robust product line-up across multiple key aesthetic categories.
Consistent with the clinical rigor of our Therapeutics division, FHL Aesthetics' product offering is rooted in our medical-grade injectable Hyaluronic Acid filler solutions. Our HA filler medical device journey was among the earliest in Korea allowing us to build a base of expertise on clinical research, development and global distribution.
FHL's growing innovative medical- and cosmetic-grade aesthetics portfolio builds on that scientific and clinical base and delivers new treatment paradigms to global markets.
With a complementary portfolio developed and manufactured in-house at our Korean R&D and manufacturing facilities as well as through high-value partnerships, we directly address patient and clinician demand for higher efficacy, less treatment-related downtime, and more flexible treatment customization.